Junjie Ma (JunJie Ma)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Venues

RSC medicinal chemistry

Future medicinal chemistry

ACS medicinal chemistry letters

Inorganic chemistry

Huaqiao University

Shenyang Pharmaceutical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Huaqiao University Jul 16 2015

China

Research Assistant :: medical college

Education History

Shenyang Pharmaceutical University Sep 01 2012 - Jun 30 2015

China

PHD :: School of Pharmaceutical Engineering

Shenyang Pharmaceutical University Sep 01 2009 - Jul 01 2012

China

MSC :: School of Pharmaceutical Engineering

Shenyang Pharmaceutical University Sep 01 2005 - Jul 02 2009

China

BSC :: School of Pharmaceutical Engineering

Publications

Xingye Wu, He Li, Han Liu, Xueyan Ding, Xinting Chen, Chenxi Yin, Yali Gao, Junjie Ma
Design, Synthesis, and Evaluation of 8-( o -Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists. ACS medicinal chemistry letters 15 (4) (2024)
Si-Hai Wu, Junjie Ma, Hui-E Peng, Ren-Hui Zheng, Zhe Zhang, Rong Yang, Lianhui Wang, Jieqing Liu, Jiao Mu, Meirong Liu, Zhong-Qiu Li, Zhong-Liang Gong, Jiang-Yang Shao, Yu-Wu Zhong
Ratiometric Imaging Detection of Amyloid-β Fibrils by a Dual-Emissive Tris-Heteroleptic Ruthenium Complex. Inorganic chemistry (2024)
Xingye Wu, He Li, Han Liu, Xueyan Ding, Xinting Chen, Chenxi Yin, Yali Gao, Junjie Ma
Design, Synthesis, and Evaluation of 8-( o -Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists. ACS medicinal chemistry letters 15 (4) (2024)
Yali Gao, Fei Li, Xin Ni, Siwang Yang, Han Liu, Xingye Wu, Jie-Qing Liu, Junjie Ma
Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat. RSC advances 13 (41) (2023)
Roufen Chen, Yali Gao, Han Liu, He Li, Wenfa Chen, Junjie Ma
Advances in research on 3C-like protease (3CL pro ) inhibitors against SARS-CoV-2 since 2020. RSC medicinal chemistry 14 (1) (2022)
He Li, Yali Gao, Junjie Ma
Advances in nonclassical phenyl bioisosteres for drug structural optimization. Future medicinal chemistry 14 (22) (2022)
Roufen Chen, Yali Gao, Han Liu, He Li, Wenfa Chen, Junjie Ma
Advances in research on 3C-like protease (3CL pro ) inhibitors against SARS-CoV-2 since 2020. RSC medicinal chemistry 14 (1) (2022)
Roufen Chen, Dandan Yuan, Junjie Ma
Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Future medicinal chemistry (2021)
Jiang-Yang Shao, Si-Hai Wu, Junjie Ma, Zhong-Liang Gong, Tian-Ge Sun, Yulong Jin, Rong Yang, Bin Sun, Yu-Wu Zhong
Ratiometric detection of amyloid-β aggregation by a dual-emissive tris-heteroleptic ruthenium complex. Chemical communications (Cambridge, England) 56 (14) (2020)
Junjie Ma, Xin Ni, Yali Gao, Kun Huang, Jiaan Liu, Yu Wang, Roufen Chen, Cuifang Wang
Identification and biological evaluation of novel benzothiazole derivatives bearing a pyridine-semicarbazone moiety as apoptosis inducers via activation of procaspase-3 to caspase-3. MedChemComm 10 (3) (2019)

Junjie Ma.css-eqlu8i{font-size:small;padding-left:4px;} (JunJie Ma)

Publication Activity (10 Years)

Top Topics

Top Venues

Junjie Ma (JunJie Ma)